Thermo Fisher Scientific (NYSE:TMO) Downgraded by Wall Street Zen to Hold

Key Points

• Thermo Fisher Scientific has been downgraded from a "buy" to a "hold" rating by analysts at Wall Street Zen.
• Despite the downgrade, a consensus among analysts still reflects a "Moderate Buy" rating with a target price of $589.38.
• Recent transactions reveal notable insider selling, with CAO Joseph R. Holmes and CEO Marc N. Casper reducing their shareholdings significantly.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Sunday.

Several other analysts have also issued reports on the stock. Raymond James Financial restated an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $589.38.

Thermo Fisher Scientific Stock Up 0.6%

TMO opened at $492.20 on Friday. The stock has a market cap of $185.86 billion, a PE ratio of 28.47, a P/E/G ratio of 2.63 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88. The business's fifty day simple moving average is $460.72 and its 200 day simple moving average is $452.89.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock worth $13,982,763 over the last three months. Company insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Large investors have recently added to or reduced their stakes in the stock. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC lifted its stake in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after buying an additional 33 shares in the last quarter. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $30,000. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $30,000. Finally, Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $31,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.